PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
13.25
Positive P/E while Biotechnology median is negative at -7.56. Peter Lynch would investigate competitive advantages in a distressed Biotechnology.
No Data
No Data available this quarter, please select a different quarter.
43.01
P/B exceeding 1.5x Biotechnology median of 3.14. Jim Chanos would check for potential asset write-down risks.
-69.03
Negative FCF while Biotechnology median P/FCF is -29.04. Seth Klarman would investigate cash flow improvement potential.
-72.44
Negative operating cash flow while Biotechnology median P/OCF is -29.37. Seth Klarman would investigate operational improvement potential.
43.01
Fair value ratio exceeding 1.5x Biotechnology median of 3.12. Jim Chanos would check for valuation bubble risks.
1.89%
Positive earnings while Biotechnology median shows losses. Peter Lynch would examine earnings quality advantage.
-1.45%
Negative FCF while Biotechnology median yield is -1.45%. Seth Klarman would investigate cash flow improvement potential.